| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | Revenue up 2%; impacted by CMO supply constraints. |
|---|---|
| Margins | EBITDA margins improved 290 bps to 34-35%. |
| Demand visibility | Strong demand for vaccines and oncology; muted in general antibiotics. |
| Management confidence | High confidence in specialty pivot and double-digit growth aspirations. |
Growth
Full-year revenue grew 2%; EBITDA grew 11%. Growth was volume-led in vaccines and specialty segments despite general medicine supply headwinds.
Outlook
Aims for double-digit growth by hitting a 10% 'freshness index' from new innovative launches.
Risks
Continued supply chain dependency on external CMOs and price ceiling risks under NLEM for 40% of the portfolio.
Last quarter's promises, checked
Delivered
- Target record PAT → Delivered >1,000 Cr (= BEAT)
- Target EBITDA margin expansion → Delivered 34% vs 31.1% (= BEAT)
- Target oncology launches → Launched Zejula and Jemperli (= BEAT)
Partly delivered
- Target 10% Freshness Index → Delivered 6% (= PARTIAL)
Missed
- Target double-digit revenue growth → Delivered 2% (= MISS)
- Target CMO supply resolution → Residual impact in Q4 (= MISS)
Earnings Call Transcript filed with NSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,815.70
- Market cap
- ₹47,700 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 44.7×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Q1 FY27 Results: Net Profit ₹237.2 Cr, Up 15.7% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹237.2 Cr · +15.7% YoY
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK India delivered double-digit EBITDA and PAT growth for FY26 despite supply disruptions. Performance was bolstered by a transition toward high-margin specialty oncology and adult vaccines, compensating for a muted general medicine segment.